Long-term effectiveness of levodopa-carbidopa intestinal gel on motor and non-motor symptoms in advanced Parkinson's disease: results of the Italian GLORIA patient population
Open Access
- 1 October 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Neurological Sciences
- Vol. 41 (10), 2929-2937
- https://doi.org/10.1007/s10072-020-04401-w
Abstract
Introduction The GLORIA registry included 375 advanced Parkinson's disease (PD) patients and evaluated the efficacy and safety of a 24-month levodopa-carbidopa intestinal gel (LCIG) treatment in routine medical care. This analysis focuses on the Italian population, 60 patients treated with LCIG in 7 specialised PD care centres. Methods Hours of "Off" and "On" time were assessed with a modified version of the Unified Parkinson's Disease Rating Scale (UPDRS) part IV items 39 and 32. Motor fluctuations, dyskinesia, non-motor symptoms, quality of life and safety were evaluated. Results Overall, 42 (70%) out of 60 patients completed the registry. LCIG treatment reduced "Off" time (- 3.3 +/- 2.7 h at month 24 (M24), P < 0.0001), increased "On" time with dyskinesia (- 2.6 +/- 5.2 h at M12, P = 0.0160), and improved UPDRS II and UPDRS III total scores at M24 (- 4.5 +/- 10.6, P = 0.0333 and - 4.9 +/- 11.7, P = 0.0229, respectively), Non-Motor Symptom Scale (NMSS) total score (- 21.8 +/- 28.5, P < 0.0001) and Parkinson's Disease Questionnaire-8 item (PDQ-8) total score (- 12.5 +/- 23.9, P = 0.0173) versus previous oral therapy. Adverse drug reactions (ADR) possibly or probably related to treatment were reported in 16 (28.6%) patients. Decreased weight (7.1%), polyneuropathy (7.1%) and abdominal pain (5.4%) were the most frequent ADRs while device malfunction (5.4%) and medical device change (5.4%) were the most reported device complaints. Conclusions LCIG improved motor fluctuations, non-motor symptoms and quality of life over 24 months while tolerability was consistent with the established safety profile.Funding Information
- AbbVie
This publication has 32 references indexed in Scilit:
- Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson diseaseActa Neurologica Scandinavica, 2012
- Parkinson’s disease: The non-motor issuesParkinsonism & Related Disorders, 2011
- Determination of minimal clinically important change in early and advanced Parkinson's diseaseMovement Disorders, 2011
- Systematic review of levodopa dose equivalency reporting in Parkinson's diseaseMovement Disorders, 2010
- Oral and Infusion Levodopa-Based Strategies for Managing Motor Complications in Patients with Parkinsonʼs DiseaseCNS Drugs, 2010
- Neurologic complications in adult living donor liver transplant patients: an underestimated factor?Zeitschrift für Neurologie, 2009
- Pharmacokinetics and pharmacodynamics of levodopaMovement Disorders, 2008
- Levodopa‐induced dyskinesiasMovement Disorders, 2007
- Impact of the motor complications of Parkinson's disease on the quality of lifeMovement Disorders, 2004
- Optimizing Levodopa Pharmacokinetics: Intestinal Infusion Versus Oral Sustained-Release TabletsClinical Neuropharmacology, 2003